Lyumjev ® ▼ (insulin lispro)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Lyumjev Summary of Product Characteristics (SmPC)

Lyumjev® ▼ (insulin lispro): Phase 1 Injection Site Reactions

In phase 1 studies, local tolerability was similar between Lyumjev and insulin lispro in patients with T1DM or T2DM

Detailed Information

Few AEs of injection site pain were observed in the phase 1b studies (NCT027033501, NCT027033372) for Lyumjev in patients with T1DM3 or in patients with T2DM.4,5

Local tolerability was similar in patients treated with Lyumjev and patients treated with IL-100 in the phase 1b studies.3-5

As with other insulin therapy, patients may experience rash, redness, inflammation, pain, bruising or itching at the site of URLi (LY900014) injection. These reactions are usually mild and usually disappear during continued treatment.6

References

1. A study of LY900014 in participants with type 1 diabetes on insulin injection therapy. ClinicalTrials.gov website. http://clinicaltrials.gov/ct/show/NCT02703350. Updated July 29, 2016. Accessed May 28, 2019.

2. A study of LY900014 in participants with type 2 diabetes on insulin injection therapy. ClinicalTrials.gov website. http://clinicaltrials.gov/ct/show/NCT02703337. Updated August 29, 2016. Accessed May 28, 2019.

3. Kazda C, Leohr J, Liu R, et al. A novel formulation of insulin lispro containing citrate and treprostinil shows faster absorption and improved postprandial glucose excursions vs. Humalog in patients with T1DM [abstract]. Diabetes. 2017;66(suppl 1):A247-A248. http://dx.doi.org/10.2337/db17-890-1488

4. Kapitza C, Leohr J, Liu R, et al. A novel formulation of insulin lispro containing citrate and treprostinil shows significantly faster absorption and an improvement in postprandial glucose excursions vs. Humalog in patients with T2DM [abstract]. Diabetes. 2017;66(suppl 1):A253-A254. http://dx.doi.org/10.2337/db17-890-1488

5. Kapitza C, Leohr J, Liu R, et al. A novel formulation of insulin lispro shows significantly faster absorption and improvement in postprandial glucose excursions versus insulin lispro in patients with type 2 diabetes [abstract]. Diabetologia. 2017;60(suppl 1):S90. http://dx.doi.org/10.1007/s00125-017-4350-z

6. Lyumjev [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

AE = adverse event

IL-100 = Humalog® (insulin lispro injection) 100 units/mL

NCT = National Clinical Trial

T1DM = type 1 diabetes mellitus

T2DM = type 2 diabetes mellitus

URLi = ultra rapid lispro

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: June 15, 2018

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question